Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $282.66 million
- Book Value:
- Revenue TTM:
- $417.44 million
- Operating Margin TTM:
- Gross Profit TTM:
- $159.96 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Accuray Incorporated had its IPO on 2007-02-08 under the ticker symbol ARAY.
The company operates in the Healthcare sector and Medical Devices industry. Accuray Incorporated has a staff strength of 1,044 employees.
Shares of Accuray Incorporated opened at $2.87 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2.81 - $2.92, and closed at $2.91.
This is a +1.39% increase from the previous day's closing price.
A total volume of 220,787 shares were traded at the close of the day’s session.
In the last one week, shares of Accuray Incorporated have increased by +3.19%.
Accuray Incorporated's Key Ratios
Accuray Incorporated has a market cap of $282.66 million, indicating a price to book ratio of 3.8916 and a price to sales ratio of 0.4253.
In the last 12-months Accuray Incorporated’s revenue was $417.44 million with a gross profit of $159.96 million and an EBITDA of $7.28 million. The EBITDA ratio measures Accuray Incorporated's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Accuray Incorporated’s operating margin was 0.55% while its return on assets stood at 0.3% with a return of equity of -23.01%.
In Q4, Accuray Incorporated’s quarterly earnings growth was a negative -96.2% while revenue growth was a negative 6.2%.
Accuray Incorporated’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.08. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Accuray Incorporated’s profitability.
Accuray Incorporated stock is trading at a EV to sales ratio of 0.7332 and a EV to EBITDA ratio of 43.2091. Its price to sales ratio in the trailing 12-months stood at 0.4253.
Accuray Incorporated stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $468.77 million
- Total Liabilities
- $184.72 million
- Operating Cash Flow
- Capital Expenditure
- $1.53 million
- Dividend Payout Ratio
Accuray Incorporated ended 2023 with $468.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $468.77 million while shareholder equity stood at $51.75 million.
Accuray Incorporated ended 2023 with $0 in deferred long-term liabilities, $184.72 million in other current liabilities, 95000.00 in common stock, $-500179000.00 in retained earnings and $57.78 million in goodwill. Its cash balance stood at $67.73 million and cash and short-term investments were $67.73 million. The company’s total short-term debt was $10,615,000 while long-term debt stood at $174.10 million.
Accuray Incorporated’s total current assets stands at $336.95 million while long-term investments were $12.28 million and short-term investments were $0. Its net receivables were $89.19 million compared to accounts payable of $33.86 million and inventory worth $155.67 million.
In 2023, Accuray Incorporated's operating cash flow was $-1534000.00 while its capital expenditure stood at $1.53 million.
Comparatively, Accuray Incorporated paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Accuray Incorporated stock is currently trading at $2.91 per share. It touched a 52-week high of $3.67 and a 52-week low of $3.67. Analysts tracking the stock have a 12-month average target price of $8.17.
Its 50-day moving average was $2.84 and 200-day moving average was $2.32 The short ratio stood at 10.65 indicating a short percent outstanding of 0%.
Around 409.1% of the company’s stock are held by insiders while 6158.5% are held by institutions.
Frequently Asked Questions About Accuray Incorporated
Similar Industry Stocks (Medical Devices)
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.